

Aeglea BioTherapeutics, Inc.

Form 3/A

April 08, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Novartis Bioventures Ltd

(Last) (First) (Middle)

131 FRONT STREET

(Street)

HAMILTON, D0 HM12

(City) (State) (Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

04/06/2016

3. Issuer Name and Ticker or Trading Symbol
Aeglea BioTherapeutics, Inc. [AGLE]

4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer ____ Other
(give title below) (specify below)

5. If Amendment, Date Original
Filed(Month/Day/Year)

04/06/2016

6. Individual or Joint/Group

Filing(Check Applicable Line)

____ Form filed by One Reporting
Person

X Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

Date Expiration
Exercisable Date

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title Amount or
Number of
Shares

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)
or Indirect
(I)
(Instr. 5)

6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Series A Preferred Stock	Â (1)	Â (1)	Common Stock	890,476	\$ 0 (1)	D (2)	Â
Series B Preferred Stock	Â (1)	Â (1)	Common Stock	1,120,448	\$ 0 (1)	D (2)	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Novartis Bioventures Ltd 131 FRONT STREET HAMILTON,Â D0Â HM12	Â	Â X	Â	Â
NOVARTIS AG LICHTSTRASSE 35 BASEL,Â V8Â CH 4056	Â	Â X	Â	Â

Signatures

/s/ Michael Jones, Deputy Chairman	04/07/2016
__Signature of Reporting Person	Date
/s/ Laurieann Chaikowsky, Authorized Signatory	04/07/2016
__Signature of Reporting Person	Date
/s/ Michael Jones, Authorized Signatory on behalf of Novartis AG	04/07/2016
__Signature of Reporting Person	Date
/s/ Laurieann Chaikowsky, Authorized Signatory on behalf of Novartis AG	04/07/2016
__Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common
- (1) Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
- These securities are held directly by Novartis Bioventures Ltd. ("Novartis Bioventures"). Novartis Bioventures is a corporation organized
- (2) under the laws of Bermuda and is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG is a corporation organized under the laws of Switzerland and is the publicly owned parent of Novartis Bioventures Ltd.

Â

Remarks:

ThisÂ amendmentÂ isÂ beingÂ filedÂ solelyÂ toÂ addÂ theÂ powerÂ ofÂ attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 3/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.